11201606428U

Text of the abstract

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1), and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1. In a preferred embodiment the PD-1 antagonist is a PD-1 antibody selected from MK-3475 and the IDO1 inhibitor is INCB024360.